Biopharm firm taps CI's Wurzer, ex-Hartford CPA to board

BY Joe Cooper

PHOTO | Contributed
PHOTO | Contributed
David Wurzer, executive vice president and chief investment officer for Connecticut Innovations, has been named to the Bioasis Technologies board of directors.
A Canada-based biopharmaceutical company, with offices in Guilford, has named Connecticut Innovations' chief investment officer and a former Hartford CPA to its board of directors.

Bioasis Technologies Inc., which develops platform technology that delivers therapeutics in treating several diseases, announced it appointed CI's Dave M. Wurzer and John E. Curran, a former partner at auditing and accounting firm Deloitte & Touche LLP, to its board.

The CPAs will serve on the the publicly traded company's audit committee and Wurzer has been appointed to the board's compensation committee.

While it's fairly common for CI executives to serve on the boards of portfolio companies, that isn't the case this time, according to CI, which does not invest in public companies.

Wurzer joined CI, the quasi-public agency of Connecticut's venture capital arm, in 2009 as the executive vice president and chief investment officer. He manages CI's $125 million venture capital portfolio that includes about 160 technology companies across the state.

Curran retired in June from Deloitte & Touche in Hartford.